<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817089</url>
  </required_header>
  <id_info>
    <org_study_id>806019</org_study_id>
    <nct_id>NCT00817089</nct_id>
  </id_info>
  <brief_title>Understanding Treatment Response With Naltrexone Among White Alcoholics</brief_title>
  <acronym>DEFINE II</acronym>
  <official_title>Defining an Endopheneotype for Alcohol Treatment With Naltrexone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study involving treatment for alcohol dependence among males of European or Asian
      decent. The ultimate aim of this line of investigation is to further establish a genetic link
      between alcohol dependence and treatment by defining an endophenotype associated with
      treatment response. The study consists of two inpatient alcohol challenge sessions with
      treatment using random assignment to either naltrexone or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the well-established efficacy of naltrexone, there are significant variations in
      individual responses to naltrexone. A critical question remains: under what circumstances and
      for which patients will naltrexone be most beneficial? Recent work at our center provides
      evidence that the mu-opioid receptor (OPRM1) gene polymorphism A118G (Asn40Asp) imparts a
      significant change in treatment response. We have shown that patients with Asn40 variant
      (absence of heavy drinking -73.9% v/s 49% response). To further consolidate our knowledge, we
      wish to test the relationship between A118G polymorphism and the subjective/objective
      measures to alcohol among alcoholics treated with naltrexone. This work is focused on
      subjects of European or Asian decent as the A118G polymorphism occurs in less than 1% of
      those of African decent.

      Up to 40 subjects will be recruited. The subjects were admitted to the UPenn Translational
      Research Center and receive two alcohol challenge sessions after pretreatment with naltrexone
      or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Groups 1 and 3 get placebo in session 1 and placebo in session 2, Groups 2 and 4 get placebo in session 1 and naltrexone in session 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biphasic Alcohol Effects Scale:Total Mood</measure>
    <time_frame>during 2nd alcohol challenge session</time_frame>
    <description>Change from baseline to peak cortisol response, during the 2nd alcohol challenge session, subjective response as measured by Biphasic Alcohol Effects Scale: Total Mood.
Biphasic Alcohol Effects Scale: Total Mood: minimum = 0, maximum = 106, higher scores indicate better outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adrenocorticotropic Hormone (ACTH) Levels</measure>
    <time_frame>during 2nd alcohol challenge session</time_frame>
    <description>Change from baseline to peak cortisol response during the 2nd alcohol challenge session, objective response as measured by Adrenocorticotropic hormone (ACTH).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Group 1 Asn40 Placebo Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each alcohol session preceded by pretreatment with placebo oral tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Asn40 Placebo Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Asp40 Placebo Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each alcohol session preceded by pretreatment with placebo oral tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Asp40 Placebo Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo pill</description>
    <arm_group_label>Group 1 Asn40 Placebo Placebo</arm_group_label>
    <arm_group_label>Group 2 Asn40 Placebo Naltrexone</arm_group_label>
    <arm_group_label>Group 3 Asp40 Placebo Placebo</arm_group_label>
    <arm_group_label>Group 4 Asp40 Placebo Naltrexone</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>50 mg of naltrexone prior to challenge session</description>
    <arm_group_label>Group 2 Asn40 Placebo Naltrexone</arm_group_label>
    <arm_group_label>Group 4 Asp40 Placebo Naltrexone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males 21 years of age or older of European or Asian decent.

          2. Has a current DSM IV diagnosis of alcohol dependence as determined by the Structural
             Clinical Interview for DSM IV (SCID-IV Mini).

          3. Drank an average of 21 drinks/week in the 60 days prior to treatment and had at least
             2 occasions of heavy drinking (5 or more drinks on a given day for men), as measured
             by the Timeline Followback (TLFB).

          4. Has adequate vision, hearing, and ability to communicate to allow study participation.

          5. Successfully completes detoxification as manifested by at least 48 consecutive hours
             of no self-reported alcohol use immediately prior to admission to the inpatient unit.

          6. Has signed a witnessed informed consent

          7. Scores below an 8 on the Clinical Inventory of Withdrawal for Alcohol (CIWA) prior to
             starting naltrexone/placebo; and 8) Can speak, print, and understand English.

        Exclusion Criteria:

          1. Meets DSM-IV criteria for dependence on any substance other than alcohol or nicotine
             in the last 6 months.

          2. Tests positive on the urine drug screen for opioids, cocaine, or amphetamine at the
             screening visit (only 1 repeat test permitted).

          3. Meets current or lifetime DSM-IV criteria for bipolar affective disorder,
             schizophrenia, or any psychotic disorder

          4. The presence of unstable or serious medical illness, including history of stroke,
             seizure disorder, severe liver disease (AST or ALT &gt; 5x normal at the time of
             randomization), or unstable cardiac disease

          5. Has taken any psychotropic medications (including disulfiram) regularly within the
             last seven days prior to randomization (14 days for fluoxetine) or needs immediate
             treatment with a psychotropic medication (with the exception of detoxification
             medications or benadryl used sparingly for sleep)

          6. Over age 64 and has evidence of severe cognitive impairment as evidenced by a
             Mini-mental status exam (MMSE) score &lt;24

          7. Has suicidal or homicidal ideation necessitating inpatient hospitalization

          8. Has been abstinent more than 14 days prior to Phase 1

          9. Is of African Descent

         10. Meets current DSM-IV criteria for for major depression (non-substance induced), PTSD,
             or panic disorder.

         11. Has significant hematological, pulmonary, endocrine, cardiovascular, renal, or
             gastrointestinal disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Oslin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <results_first_submitted>September 11, 2019</results_first_submitted>
  <results_first_submitted_qc>October 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 21, 2019</results_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>David Oslin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Asn40 Placebo Placebo</title>
          <description>Asn40: Placebo, Placebo
Each alcohol session preceded by pretreatment with placebo.
Placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Asn40 Placebo Naltrexone</title>
          <description>Asn40: Placebo, Naltrexone
The first alcohol challenge session preceded by pretreatment with placebo. The second alcohol challenge session preceded by pretreatment with naltrexone 50 mg as a single dose.
Placebo: placebo pills
naltrexone: 50 mg of naltrexone prior to challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Asp40 Placebo Placebo</title>
          <description>Asp40: Placebo, Placebo
Each alcohol challenge session preceded by pretreatment with placebo.
Placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="P4">
          <title>Group 4: Asp40 Placebo Naltrexone</title>
          <description>Asp40: Placebo, Naltrexone
The first alcohol challenge session preceded by pretreatment with placebo. The second challegne alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
Placebo: placebo pills
naltrexone: 50 mg of naltrexone prior to challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Alcohol Challenge</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Alcohol Challenge</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Asn40 Placebo Placebo</title>
          <description>Asn40: Placebo, Placebo
Each alcohol challenge session preceded by pretreatment with placebo
Placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Asn40 Placebo Naltrexone</title>
          <description>Asn40: Placebo, Naltrexone
The first alcohol challenge session preceded by pretreatment with placebo. The second challegne alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
Placebo: placebo pills
naltrexone: 50 mg of naltrexone prior to challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Asp40 Placebo Placebo</title>
          <description>Asp40: Placebo, Placebo
Each alcohol challenge session preceded by pretreatment with placebo
Placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="B4">
          <title>Group 4: Asp40 Placebo Naltrexone</title>
          <description>Asp40: Placebo, Naltrexone
The first alcohol challenge session preceded by pretreatment with placebo. The second alcohol challenge session preceded by pretreatment with naltrexone 50 mg as a single dose.
Placebo: placebo pills
naltrexone: 50 mg of naltrexone prior to challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;21 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 21 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biphasic Alcohol Effects Scale:Total Mood</title>
        <description>Change from baseline to peak cortisol response, during the 2nd alcohol challenge session, subjective response as measured by Biphasic Alcohol Effects Scale: Total Mood.
Biphasic Alcohol Effects Scale: Total Mood: minimum = 0, maximum = 106, higher scores indicate better outcomes.</description>
        <time_frame>during 2nd alcohol challenge session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Asn40 Placebo Placebo</title>
            <description>Asn40: Placebo, Placebo
Each alcohol challenge session preceded by pretreatment with placebo.
Placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Asn40 Placebo Naltrexone</title>
            <description>Asn40: Placebo, Naltrexone
The first alcohol challenge session preceded by pretreatment with placebo. The second alcohol challenge session preceded by pretreatment with naltrexone 50 mg as a single dose.
Placebo: placebo pills
naltrexone: 50 mg of naltrexone prior to challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Asp40 Placebo Placebo</title>
            <description>Asp40: Placebo, Placebo
Each alcohol challenge session preceded by pretreatment with placebo.
Placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Asp40 Placebo Naltrexone</title>
            <description>Asp40: Placebo, Naltrexone
The first alcohol challenge session preceded by pretreatment with placebo. The second alcohol challenge session preceded by pretreatment with naltrexone 50 mg as a single dose.
Placebo: placebo pills
naltrexone: 50 mg of naltrexone prior to challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
          </group>
        </group_list>
        <measure>
          <title>Biphasic Alcohol Effects Scale:Total Mood</title>
          <description>Change from baseline to peak cortisol response, during the 2nd alcohol challenge session, subjective response as measured by Biphasic Alcohol Effects Scale: Total Mood.
Biphasic Alcohol Effects Scale: Total Mood: minimum = 0, maximum = 106, higher scores indicate better outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="9.53"/>
                    <measurement group_id="O2" value="3.57" spread="18.46"/>
                    <measurement group_id="O3" value="6.50" spread="4.04"/>
                    <measurement group_id="O4" value="3.20" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adrenocorticotropic Hormone (ACTH) Levels</title>
        <description>Change from baseline to peak cortisol response during the 2nd alcohol challenge session, objective response as measured by Adrenocorticotropic hormone (ACTH).</description>
        <time_frame>during 2nd alcohol challenge session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Asn40 Placebo Placebo</title>
            <description>Asn40: Placebo, Placebo
Each alcohol challenge session preceded by pretreatment with placebo.
Placebo: placebo pills
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Asn40 Placebo Naltrexone</title>
            <description>Asn40: Placebo, Naltrexone
The first alcohol challegne session preceded by pretreatment with placebo. The second alcohol challenge session preceded by pretreatment with naltrexone 50 mg as a single dose.
Placebo: placebo pills
Naltrexone: 50 mg of naltrexone prior to challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
          </group>
          <group group_id="O3">
            <title>Group 3 Asp40 Placebo Placebo</title>
            <description>Asp40: Placebo, Placebo Each alcohol challenge session preceded by pretreatment with placebo oral tablet
Placebo Oral Tablet: Placebo pill
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
          </group>
          <group group_id="O4">
            <title>Group 4 Asp40 Placebo Naltrexone</title>
            <description>Asp40: Placebo, Naltrexone
The first alcohol challenge session preceded by pretreatment with placebo oral tablet. The second alcohol challenge session preceded by pretreatment with naltrexone 50 mg as a single dose.
Placebo Oral Tablet: Placebo pill
Naltrexone: 50 mg of naltrexone prior to challenge session
alcohol: 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
          </group>
        </group_list>
        <measure>
          <title>Adrenocorticotropic Hormone (ACTH) Levels</title>
          <description>Change from baseline to peak cortisol response during the 2nd alcohol challenge session, objective response as measured by Adrenocorticotropic hormone (ACTH).</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.83" spread="14.34"/>
                    <measurement group_id="O2" value="3.86" spread="7.47"/>
                    <measurement group_id="O3" value="5.25" spread="8.42"/>
                    <measurement group_id="O4" value="-3.20" spread="14.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 hours</time_frame>
      <desc>Adverse events were tracked in the 36 hours after the second alcohol challenge session</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Asn40 Placebo Placebo</title>
          <description>Asn40: placebo, placebo
Each alcohol challenge session preceded by pretreatment with placebo.
placebo: placebo pills
alcohol : 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Asn40 Placebo Naltrexone</title>
          <description>Asn40: placebo, naltrexone
The first alcohol challenge session preceded by pretreatment with placebo. The second alcohol challenge session preceded by pretreatment with naltrexone 50 mg as a single dose.
placebo: placebo pills
naltrexone : 50 mg of naltrexone prior to challenge session
alcohol : 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Asp40 Placebo Placebo</title>
          <description>Asp40: placebo, placebo prior
Each alcohol challenge session preceded by pretreatment with placebo.
placebo: placebo pills
alcohol : 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
        <group group_id="E4">
          <title>Group 4: Asp40 Placebo Naltrexone</title>
          <description>Asp40: placebo, naltrexone
The first alcohol challenge session preceded by pretreatment with placebo. The second alcohol challenge session preceded by pretreatment with naltrexone 50 mg as a single dose.
placebo: placebo pills
naltrexone : 50 mg of naltrexone prior to challenge session
alcohol : 190 proof alcohol prepared to 11% volume mixed with fruit juice</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Oslin</name_or_title>
      <organization>UPENN</organization>
      <phone>215 823 5894</phone>
      <email>oslin@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

